natgillin/translations-raw huggingface dataset:
Two Gelman ITLC-SG strips (2 cm x 10 cm)
Dva Gelman ITLC-GS trakova (2 cm x 10 cm)
Two hundred and fifteen HBeAg negative (GS-US-174-0102, n = 125) and HBeAg positive (GS-US-174-0103, n = 90) patients initially randomised to double-blind adefovir dipivoxil treatment and then switched to open-label tenofovir disoproxil fumarate treatment were evaluated for genotypic changes in HBV polymerase from baseline.
Pri 215 bolnikih, negativnih na HBeAg (GS-US-174-0102, n = 125) in pozitivnih na HBeAg (GS-US-174-0103, n = 90), ki so jih na začetku naključno razporedili v skupino, ki je prejemala dvojno slepo zdravljenje z dipivoksiladefoviratom, nato pa so nadaljevali z odprtim zdravljenjem z dizoproksiltenofovirijevim fumaratom, so ocenili genotipske spremembe HBV-polimeraze od izhodiščne točke.
Two hundred and fifty-six patients, ranging from 16 to 91 years in age, were randomised to treatment and received at least one dose of study medication.
Na zdravljenje je bilo randomiziranih 256 bolnikov, starih od 16 do 91 let, in dobili so vsaj en odmerek raziskovanega zdravila.
Two hundred twenty-four patients were included in the primary efficacy analysis (MITT analysis) of response at the end of IV study therapy; favourable response rates for the treatment of invasive candidiasis were comparable for caspofungin (73 % [80/109]) and amphotericin B (62 % [71/115]) [% difference 12.7 (95.6 % CI -0.7, 26.0)].
V analizo primarne učinkovitosti (analiza MITT; MITT – modified intention-to-treat) odziva na koncu intravenskega raziskovanega zdravljenja je bilo vključenih 224 bolnikov; deleža ugodnega odziva pri zdravljenju invazivne kandidiaze s kaspofunginom (73 % [80/109]) in amfotericinom B (62 % [71/115]) sta bila podobna [% razlike 12,7 (95,6-odstotni IZ -0,7, 26,0)].
Two immunisation schedules can be recommended:
Priporočimo lahko dve shemi primarnega cepljenja:
Two infusion bags should be prepared for the infusion on Days 1 and 2 (100 mg for Day 1 and 900 mg for Day 2).
Za infundiranje 1. in 2. dan je treba pripraviti dve infuzijski vrečki (100 mg za 1. dan in 900 mg za 2. dan).
Two injections are given 21 days apart in animals from the age of 2 weeks where there are no antibodies against IBR virus from the mother.
Če ni prisotnih nobenih protiteles proti virusu IBR od matere, se živalim od starosti dveh tednov v presledku 21 dni dasta dve injekciji.
two injections with an interval of one month followed by a third injection 6 months after the first administration (0,1,6 months) if immunity is needed quickly: three injections with an interval of one month and a fourth dose 1 year later (0,1,2,12 months).
dve injekciji v enomesečnem presledku, ki jima sledi tretja injekcija 6 mesecev po prvi (0, 1 in 6 mesecev). če je imunost treba doseči hitro: tri injekcije v presledku enega meseca in četrti odmerek 1 leto pozneje (0, 1, 2, 12 mesecev).
Two large long-term follow-up studies enrolled 1,071 patients and 567 patients after treatment in prior studies with non-pegylated interferon alfa-2b (with or without ribavirin) and pegylated interferon alfa- 2b (with or without ribavirin), respectively.
V dve veliki, dolgoročni študiji spremljanja bolnikov po zdravljenju v prejšnjih študijah so vključili skupaj 1071 bolnikov po končanem zdravljenju z nepegiliranim interferonom alfa-2b (z ribavirinom ali brez njega) ter 567 bolnikov po končanem zdravljenju s pegiliranim interferonom alfa-2b (z ribavirinom ali brez njega).
Two large long-term follow-up studies enrolled 1,071 patients and 567 patients after treatment in prior studies with non-pegylated interferon alfa-2b (with or without ribavirin) and pegylated interferon alfa-2b (with or without ribavirin), respectively.
V dve veliki, dolgoročni študiji spremljanja bolnikov po zdravljenju v prejšnjih študijah so vključili skupaj 1.071 bolnikov po končanem zdravljenju z nepegiliranim interferonom alfa-2b (z ali brez ribavirina) ter 567 bolnikov po končanem zdravljenju s pegiliranim interferonom alfa-2b (z ali brez ribavirina).
Two large long-term follow-up studies enrolled 1,071 patients and 567 patients after treatment in prior studies with nonpegylated interferon alfa-2b (with or without ribavirin) and pegylated interferon alfa-2b (with or without ribavirin), respectively.
V dve veliki, dolgoročni študiji spremljanja bolnikov po zdravljenju v prejšnjih študijah so vključili skupaj 1071 bolnikov po končanem zdravljenju z nepegiliranim interferonom alfa-2b (z ali brez ribavirina) ter 567 bolnikov po končanem zdravljenju s pegiliranim interferonom alfa-2b (z ali brez ribavirina).
Two large Phase III trials were designed to investigate the treatment effect of Avastin in combination with two individual chemotherapy agents, as measured by the primary endpoint of PFS.
Za preučevanje učinka zdravljenja z zdravilom Avastin v kombinaciji z dvema posameznima kemoterapevtskima zdraviloma sta bili zasnovani dve veliki preskušanji faze III, v katerih je bil primarni cilj preživetje brez napredovanja bolezni (PFS, progression free survival).
Two large prospective randomised studies, the HiLo study (Mallick) and the ESTIMABL study (Schlumberger), compared methods of thyroid remnant ablation in patients with differentiated thyroid cancer who had been thyroidectomised.
V dveh velikih prospektivnih, randomiziranih študijah - študiji HiLo (Mallick) in študiji ESTIMABL (Schlumberger) - so primerjali metode ablacije tiroidnih ostankov pri bolnikih z diferenciranim rakom ščitnice, katerim so odstranili ščitnico.
Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
Uporabo zaviralca ACE v kombinaciji z blokatorjem receptorjev angiotenzina II so raziskali v dveh velikih randomiziranih, kontroliranih preskušanjih: ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) in VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes).
Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) andVA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
Uporabo zaviralca ACE v kombinaciji z blokatorjem receptorjev angiotenzina II so raziskali v dveh velikih randomiziranih, kontroliranih preskušanjih: ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) in VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes).
Two large randomised, controlled trials (ONTARGET [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] and VA NEPHRON-D [The Veterans Affairs Nephropathy in Diabetes]) have examined the use of the combination of an ACE inhibitor with an angiotensin II receptor blocker (ARB).
Uporabo zaviralca ACE v kombinaciji z antagonistom angiotenzinskih receptorjev II (ARB) so raziskali v dveh velikih randomiziranih, kontroliranih preskušanjih: ONTARGET [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] in VA NEPHRON-D [The Veterans Affairs Nephropathy in Diabetes].
Two large randomised, controlled trials(ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
Uporabo zaviralca ACE v kombinaciji z blokatorjem receptorjev angiotenzina II so raziskali v dveh velikih randomiziranih, kontroliranih preskušanjih: ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) in VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes).
Two main studies have also been carried out involving a total of 353 patients with lower risk myelodysplastic syndromes.
Dve glavni študiji sta bili izvedeni tudi pri 353 bolnikih z mielodisplastičnim sindromom z nizkim tveganjem.
Two main studies have been performed to compare Pradaxa (either 220 or 150 mg a day) with enoxaparin (another anticoagulant) in patients who had undergone a hip or knee replacement.
Izvedeni sta bili dve glavni študiji, v katerih so zdravilo Pradaxa (220 mg ali 150 mg dnevno) primerjali z enoksaparinom (drugim antikoagulantom) pri bolnikih, ki so jim operativno vstavili umetni kolk ali koleno.
Two main studies have evaluated the addition of Truvada to standard preventative measures for pre- exposure prophylaxis.
V dveh glavnih študijah so ocenjevali dodajanje zdravila Truvada standardnim preprečevalnim ukrepom predekspozicijske profilakse.
Two main studies have examined the effects of Truvada’s active substances, emtricitabine and tenofovir disoproxil, in adults infected with HIV-1 who had not been treated before.
V dveh glavnih študijah so proučevali učinke zdravilnih učinkovin zdravila Truvada, emtricitibina in tenofovir dizoproksila, pri odraslih, okuženih z virusom HIV-1, ki pred tem še niso bili zdravljeni.
Two main studies in over 5,100 adult patients with symptoms of DVT or PE, and who were initially treated with an injectable anticoagulant, compared Pradaxa with warfarin.
V dveh glavnih študijah, v katerih je sodelovalo več kot 5 100 odraslih bolnikov s simptomi globoke venske tromboze ali pljučne embolije, ki so bili najprej zdravljeni z injekcijami antikoagulantov, so zdravilo Pradaxa primerjali z varfarinom.
Two main studies of Elocta showed that the medicine is effective at both preventing and treating bleeding episodes.
Glavni študiji z zdravilom Elocta sta pokazali, da je učinkovito pri preprečevanju in zdravljenju epizod krvavitve.
Two main studies were performed comparing Fampyra with placebo (a dummy treatment) in 540 patients with multiple sclerosis.
Izvedeni sta bili dve glavni študiji, v katerih so zdravilo Fampyra primerjali s placebom (zdravilo brez zdravilne učinkovine) pri 540 bolnikih z multiplo sklerozo.
Two measuring scoops are provided in the medicine box:
V škatli sta dve merici:
Two medicines are bioequivalent when they produce the same levels of the active substance in the body.
Dve zdravili sta biološko enakovredni, kadar v telesu ustvarita enako raven zdravilne učinkovine.
Two metabolites – most probably resulting from hepatic metabolism (major enzyme is CYP2C9) – were identified both in urine and faeces: the hydroxy derivative and the carboxy derivative.
Dva metabolita – verjetno zaradi jetrne presnove (glavni encim je CYP2C9) – sta bila najdena tako v urinu kot tudi v blatu: hidroksi- derivat in karboksi-derivat.
Two metabolites, the mono-desmethyl and the N- oxide, were detected at low concentrations in the urine.
Dva presnovka, monodesmetil in N-oksid, pa so v urinu izmerili v majhnih koncentracijah.
Two minor plasma metabolites were detected (≤ 9% and ≤ 5% of total plasma radioactivity exposure).
Odkrili so tudi dva manj pomembna presnovka v plazmi (≤ 9 % in ≤ 5 % celotne izpostavljenosti plazme radioaktivnosti).
two MIRAPEXIN 0.26 mg prolonged-release tablets.
dve MIRAPEXIN 0,26 mg tableti s podaljšanim sproščanjem
two MIRAPEXIN 0.52 mg prolonged-release tablets, OR
dve MIRAPEXIN 0,52 mg tableti s podaljšanim sproščanjem ALI
Two months after completion of INCIVO treatment, hormonal contraceptives are again appropriate as one of the two required effective methods of birth control.
Dva meseca po zaključku zdravljenja z zdravilom INCIVO so hormonski kontraceptivi spet primerni kot ena od 2 zahtevanih učinkovitih kontracepcijskih metod.
Two more main studies looked at the action of Xgeva in adults or full-grown adolescents with giant cell tumour of bone that was unsuitable for surgery or in whom surgery would have resulted in severe complications like amputation of a limb.
V nadaljnjih dveh glavnih študijah so proučevali delovanje zdravila Xgeva pri odraslih ali popolnoma razvitih mladostnikih z gigantocelularnim kostnim tumorjem, pri katerih kirurški poseg ni bil primeren ali bi povzročil hude zaplete, na primer amputacijo uda.
Two multi-centre studies were conducted (one in the USA and one in Europe) to compare the efficacy, safety and acceptability of firocoxib under field conditions with that of phenybutazone (in the USA) or vedaprofen (in Europe).
Opravljeni sta bili dve multicentrični študiji (ena v ZDA in ena v Evropi), v katerih so učinkovitost, varnost in sprejemljivost firokoksiba v pogojih na terenu primerjali s fenibutazonom (v ZDA) ali vedaprofenom (v Evropi).
Two multi-centre, double-blind, placebo-controlled six month studies in 562 (INTIMATE SM1) and 533 (INTIMATE SM2) oophorectomised and hysterectomised women (surgically induced menopause), aged 20 to 70 years, with HSDD on concomitant estrogen were used to evaluate the efficacy and safety of Livensa.
Učinkovitost in varnost zdravila Livensa so ocenili v dveh multicentričnih, dvojno slepih, s placebom nadzorovanih šestmesečnih študijah pri 562 (INTIMATE SM1) in 533 (INTIMATE SM2) ženskah z ooforektomijo in histerektomijo (kirurško sproženo menopavzo) s HSDD, starih od 20 do 70 let, ki so sočasno prejemale estrogen.
Two multi-centre, open-label, cross-over, uncontrolled, randomized studies in previously treated adults/adolescents with severe haemophilia A (< 1%) and one multicentre, open label, uncontrolled study in previously treated children < 12 years with severe haemophilia A were conducted.
Izvedli so dve multicentrični, odprti, navzkrižni, nenadzorovani, randomizirani študiji pri predhodno zdravljenih odraslih/mladostnikih s hudo obliko hemofilije A (< 1 %) in eno multicentrično, odprto, nenadzorovano študijo pri predhodno zdravljenih otrocih < 12 let s hudo obliko hemofilije A.
Two mutations conferred a 7 to 8 fold change in abacavir susceptibility and combinations of three mutations were required to confer more than an 8 fold change in susceptibility.
Dve mutaciji sta povzročili 7- do 8-kratno spremembo občutljivosti na abakavir, za več kot 8-kratno spremembo občutljivosti pa so bile potrebne kombinacije treh mutacij.
Two non-conjugated metabolites (XL184-N-oxide and XL184 amide cleavage product), which possess <1% of the on-target kinase inhibition potency of parent cabozantinib, each represent <10% of total drug-related plasma exposure.
Dva nekonjugirana presnovka (XL184-N-oksid in produkt cepitve XL184 amida), ki imata < 1 % ciljne zaviralne učinkovitosti kinaze izhodiščnega kabozantiniba, vsak predstavljata < 10 % skupne z zdravilom povezane izpostavljenosti v plazmi.
Two non-conjugated metabolites (XL184-N-oxide and XL184 amide cleavage product), which possess <1% of the on-target kinase inhibition potency of parent cabozantinib, each represent <10% of total drug-related plasma exposure.
Dva nekonjugirana presnovka (XL184-N-oksid in produkt cepitve XL184 amida), ki imata zaviralno učinkovitost na kinazo, ki je manjša od < 1 % ciljne učinkovitosti izhodiščnega kabozantiniba, vsak predstavljata < 10 % skupne z zdravilom povezane izpostavljenosti v plazmi.
Two of the active substances in Broadline, eprinomectin and praziquantel, act as ‘endoparasiticides’.
Drugi dve zdravilni učinkovini v zdravilu Broadline, eprinomektin in prazikvantel, delujeta kot „endoparazitika“.
Two of the active substances in Broadline, fipronil and (S)-methoprene, act as ‘ectoparasiticides’.
Dve zdravilni učinkovini v zdravilu Broadline, fipronil in (S)-metopren, delujeta kot „ektoparazitika“.
Two of the studies compared Lucentis with a sham injection.
V dveh študijah so zdravilo Lucentis primerjali z navidezno injekcijo.
Two of the studies found no difference in risk of neuropsychiatric hospitalisations between varenicline users and nicotine patch users (Hazard Ratio [HR] 1.14; 95% Confidence Interval [CI]: 0.56-2.34 in the first study, and 0.76; 95% CI: 0.40-1.46 in the second study).
V dveh od teh študij niso ugotovili razlike v tveganju za nevropsihiatrične hospitalizacije med uporabniki vareniklina in uporabniki nikotinskih obližev (razmerje ogroženosti (HR - hazard ratio) 1,14; 95 % interval zaupanja (IZ): 0,56–2,34 v prvi študiji, in 0,76; 95 % IZ: 0,40–1,46 v drugi študiji).
Two of the studies found no difference in risk of neuropsychiatric hospitalisations between varenicline users and nicotine patch users (Hazard Ratio [HR] 1.14; 95% Confidence Interval [CI]: 0.56–2.34 in the first study, and 0.76; 95% CI: 0.40-1.46 in the second study).
V dveh od teh študij niso ugotovili razlike v tveganju za nevropsihiatrične hospitalizacije med uporabniki vareniklina in uporabniki nikotinskih obližev (razmerje ogroženosti (HR - hazard ratio) 1,14; 95 % interval zaupanja (IZ): 0,56–2,34 v prvi študiji, in 0,76; 95 % IZ: 0,40–1,46 v drugi študiji).
Two of the studies looked at the effects of TachoSil in stopping bleeding.
v dveh študijah so raziskovali vpliv zdravila TachoSil na zaustavitev krvavitve.
Two of the studies specifically looked at the effectiveness of Imvanex as a booster.
V dveh študijah so posebej proučevali učinkovitost cepiva Imvanex kot poživitvenega cepljenja.
Two of these subjects on placebo had DVT, one with Grade 2 and one with Grade 3.
Dva od bolnikov v skupini s placebom sta imela globoko vensko trombozo, en 2. stopnje in drugi 3. stopnje.
Two of three delavirdine- resistant clinical isolates examined were cross-resistant to efavirenz and contained the K103N substitution.
Dva od treh kliničnih izolatov, rezistentnih na delavirdin, ki so jih preučevali, sta bila navzkrižno rezistentna na efavirenz in sta vsebovala substitucijo K103N.
two Oprymea 0.26 mg prolonged-release tablets.
Dve Oprymea 0,26 mg tableti s podaljšanim sproščanjem
two Oprymea 0.52 mg prolonged-release tablets, OR
Dve Oprymea 0,52 mg tableti s podaljšanim sproščanjem ALI
Two options can be followed:
Imate dve možnosti: možnost:
Two other studies compared the above fixed dose-combinations of umeclidinium and vilanterol with another COPD medicine called tiotropium and one study compared only the lower dose of umeclidinium and vilanterol (55 micrograms/ 22 micrograms) against tiotropium.
V dveh drugih študijah so primerjali zgornji kombinaciji umeklidinija in vilanterola s fiksnim odmerkom z drugim zdravilom za KOPB, tiotropijem, v eni od študij pa so primerjali le nižji odmerek umeklidinija in vilanterola (55 mikrogramov/22 mikrogramov) s tiotropijem.
Two other studies compared the same two fixed dose-combinations of umeclidinium bromide and vilanterol with another COPD medicine called tiotropium.
V drugih dveh študijah so primerjali isti kombinaciji umeklidinijevega bromida in vilanterola v fiksnem odmerku z drugim zdravilom za zdravljenje KOPB, imenovanim tiotripij.
Two other studies in 101 patients looked at how effective Kuvan was at allowing the patients to consume foods containing phenylalanine while keeping blood phenylalanine at target levels (i.e. phenylalanine tolerance)
V drugih dveh študijah, v katerih je sodeloval 101 bolnik, so proučevali toleranco na fenilalanin, tj. učinkovitost zdravila pri tem, da bolnikom omogoči, da uživajo hrano, ki vsebuje fenilalanin, istočasno pa njegovo raven v krvi ohranjajo na ciljni ravni.
Two other studies showed that dapagliflozin taken with metformin and another diabetes medicine, sitagliptin or insulin, for 24 weeks, further decreased HbA1c: the dapagliflozin combination decreased HbA1c levels by 0.40% more than placebo and metformin when added to sitagliptin, and by 0.61% more than placebo and metformin when added to insulin.
Dve drugi študiji sta pokazali, da je dapagliflozin v kombinaciji z metforminom in drugim zdravilom za sladkorno bolezen, sitagliptinom ali insulinom, po 24 tednih jemanja dodatno znižal ravni HbA1c: ko so ga dodajali sitagliptinu, je dapagliflozin v kombinaciji z metforminom znižal ravni HbA1c za 0,40 % več kot placebo in metformin, ko so ga dodajali insulinu, pa za 0,61 % več kot placebo in metformin.
Two pack sizes are available for Norvir oral solution:
Peroralna raztopina Norvir je na voljo v dveh pakiranjih:
Two pack sizes are available: 1 bottle with 60 tablets, and 3 bottles of 60 tablets each.
Na voljo sta dve velikosti pakiranja: 1 plastenka s 60 tabletami in 3 plastenke po 60 tablet.
Two pack sizes are available: 1 bottle with 60 tablets, and 3 bottles of 60 tablets.
Na voljo sta dve velikosti pakiranja: 1 plastenka s 60 tabletami in 3 plastenke po 60 tablet.
Two patients (2/117, 1.7%) using the SC pre-filled pen experienced local injection site reactions.
Pri dveh bolnikih (2/117; 1,7 %), ki sta s.c. uporabljala napolnjen injekcijski peresnik, so poročali o pojavu lokalnih reakcij na mestu injiciranja.
Two patients (<1%) who received sunitinib were diagnosed with congestive heart failure (CHF).
Pri dveh bolnikih (< 1 %), ki sta prejemala sunitinib, so diagnosticirali kongestivno srčno popuščanje.
Two patients experienced injection site reactions that led to reductions of their asfotase alfa dose.
Dva bolnika sta imela reakcije na mestu injiciranja, zaradi katerih je bil odmerek asfotaze alfa zmanjšan.
Two patients in the LDV/SOF 12-week treatment arm, one patient in the LDV/SOF+RBV 12-week treatment arm, two patients in the LDV/SOF 24-week treatment arm, and two patients in the LDV/SOF+RBV 24-week treatment arm did not have a confirmed genotype 1 subtype.
Dva bolnika v skupini 12-tedenskega zdravljenja z LDV/SOF, en bolnik v skupini 12-tedenskega zdravljenja z LDV/SOF+RBV, dva bolnika v skupini 24-tedenskega zdravljenja z LDV/SOF in dva bolnika v skupini 24-tedenskega zdravljenja z LDV/SOF+RBV niso imeli potrjenega podtipa genotipa 1.
Two patients on the recommended teduglutide dose were weaned off parenteral nutrition by Week 24.
Dvema bolnikoma na priporočenem odmerku teduglutida je bilo mogoče ukiniti parenteralno prehrano po 24 tednih.
Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis studies developed clinical signs suggestive of new-onset lupus-like syndrome.
V vseh študijah revmatoidnega artritisa in psoriatičnega artritisa so se klinični znaki, ki so nakazovali novonastali lupusni sindrom, pojavili pri 2 od 3441 bolnikov, zdravljenih z zdravilom Humira.
Two patients, including the one patient with a Grade 3 case (tubulointerstitial nephritis), received high-dose corticosteroids (at least 40 mg prednisone equivalents) at a median initial dose of 0.8 mg/kg (range: 0.5-1.2) for a median duration of
Dva bolnika, vključno z enim bolnikom s primerom stopnje 3 (tubulointersticijski nefritis), sta prejemala visoke odmerke kortikosteroidov (odmerke, ki so ustrezali vsaj 40 mg prednizona) z medianim začetnim odmerkom 0,8 mg/kg (razpon: 0,5-1,2), zdravljenje pa je mediano trajalo 5,3 tedna (razpon: 0,9-9,7).
Two percent of patients had percent predicted FVC below 50% and 21% of patients had a percent predicted DLCO below 35% at Baseline.
Dva odstotka bolnikov je imelo ob izhodišču odstotek predvidene FVC pod 50 %, 21 % bolnikov pa je imelo odstotek predvidene in difuzijsko kapaciteto za CO (DLCO, - carbon monoxide diffusing capacity) pod 35 %.
Two percent of the infusion reactions led to discontinuation of treatment.
V 2 % so infuzijske reakcije povzročile prenehanje zdravljenja.
Two Phase II multicentre, randomised, double-masked, parallel group studies were conducted in Japan, and two Phase III multicentre, randomised (2:1), double-masked, parallel group, placebo- controlled studies were conducted in the US to assess the clinical safety and efficacy of Yellox dosed twice daily in the treatment of post-operative inflammation in patients undergoing cataract surgery.
Na Japonskem so izvedli dve multicentrični, randomizirani, dvojno slepi študiji 2. faze z vzporednimi skupinami in v ZDA dve multicentrični, randomizirani (2 : 1), dvojno slepi, s placebom nadzorovani študiji 3. faze z vzporednimi skupinami, v katerih so ocenili klinično varnost in učinkovitost zdravila Yellox v odmerku dvakrat na dan pri zdravljenju pooperacijskega vnetja pri bolnikih, pri katerih so opravili kirurško odstranitev katarakte.